Synthetic Diversity
Defined sequence variation across binding loops for broad epitope exploration.
Synthetic Yeast Display Antibody Discovery CRO
Yeast Display Antibody Discovery from Synthetic Drug-Like Libraries
DuneX Biosciences helps biotech teams discover and optimize scFv and VHH binders from synthetic, drug-discovery-oriented yeast display libraries, using FACS-based selection, sequence recovery, clone ranking, and practical next-step recommendations.
108-109Synthetic library-scale screening
Drug-likeDiscovery-oriented library design
scFv / VHHFlexible binder modalities
Synthetic Library Engine
Built on synthetic libraries designed for discovery quality
DuneX yeast display campaigns use synthetic scFv and VHH library designs built to explore broad sequence space while preserving antibody-like framework behavior. The result is a practical path to diverse binders, sequence-verified panels, and follow-on optimization.
Synthetic diversityDrug-like frameworksFACS-selectable displaySequence-verified outputs
Drug-Like Frameworks
Human scFv and compact VHH formats selected for practical downstream discovery paths.
FACS-Selectable Display
Expression and binding signals can be monitored round by round under tunable stringency.
Sequence-Verified Outputs
Recovered clones are ranked with sequence identity, enrichment behavior, and recommended next steps.
What We Do
Antibody discovery services built around synthetic yeast display libraries
Choose human scFv for standard antibody workflows, VHH for compact formats and difficult epitopes, or evolve existing hits using focused diversification and high-stringency selection.
DuneX-Nova™
Human scFv Discovery
Synthetic human scFv discovery for IgG transition pathways and conventional antibody development.
View Binder Discovery →DuneX-Nano™
VHH / Nanobody Discovery
Synthetic VHH / nanobody discovery for recessed epitopes, difficult targets, and modular formats.
Compare Formats →DuneX-Evolve™
Affinity Maturation
Focused diversification and high-stringency selection to improve affinity, off-rate behavior, and specificity.
Optimize Hits →Why Yeast Display
Why yeast display strengthens antibody discovery programs
Yeast display gives teams controlled selection pressure, synthetic library diversity, recoverable sequences, and practical decision data for large-scale antibody discovery.
Quantitative Selection Pressure
FACS enables controlled antigen concentration, expression-aware gating, and round-by-round monitoring.
Recoverable Sequences
Binding phenotype is linked to clone identity for fast ranking and follow-up.
Flexible Stringency
Equilibrium, off-rate, and competitive selection modes can be tuned by campaign goal.
Synthetic Library Control
Defined library design supports reproducible campaign logic and cleaner interpretation than uncontrolled starting repertoires.
Program Metrics
Key discovery signals buyers can evaluate quickly
Scope depends on antigen readiness, target complexity, assay format, and campaign goals.
Synthetic Library-Scale Screening
Campaign-scale diversity for broad binder exploration.
Focused Pilot Discovery Timeline
Typical path to clone ranking when reagents are ready.
Iterative FACS Enrichment
Selection rounds designed to show measurable progression.
Typical Prioritized Panel Range
Output clone range depends on scope and package.
Synthetic Library Design
Designed for discovery campaigns where downstream developability matters.
Confidentiality & Facility
Project handling built for confidential discovery work
Based in Hayward, CA within the Bay Area biotech ecosystem, DuneX supports yeast display discovery using FACS-based screening, molecular biology workflows, and access to shared laboratory infrastructure.
NDA-First Discussions
Confidential discussion model before sensitive target or program details are exchanged.
Client-Owned Sequences and Reports
Sequences, ranked panels, and project deliverables are structured for client control.
Project-Specific Data Organization
Client-specific materials and data are handled with clear operational separation.
Bay Area Lab Network Access
Located in Hayward, DuneX is positioned near biotech partners, shared infrastructure, and research collaborators.
FAQ
Common questions
What targets can DuneX support?
Programs can be scoped around purified proteins, Fc fusions, bead-coupled targets, and suitable cell-surface targets depending on antigen format and detection strategy.
Do you offer both human scFv and VHH discovery?
Yes. DuneX-Nova supports human scFv discovery, while DuneX-Nano supports compact VHH / nanobody discovery. Parallel campaigns can be considered when epitope diversity is critical.
How are projects handled?
Each campaign is scoped with clear milestones, defined deliverables, and client-facing reporting. For specialized downstream characterization, DuneX can coordinate suitable follow-on paths depending on project needs.
What is a typical project timeline?
Focused discovery campaigns typically reach clone ranking within 3-6 weeks when antigen readiness, labeling strategy, and assay conditions are aligned.
What do you mean by synthetic drug-like libraries?
"Drug-like" refers to discovery-oriented design logic and downstream development awareness, not GMP or clinical-grade manufacturing.
Can DuneX improve an existing antibody hit?
Yes. DuneX-Evolve affinity maturation campaigns use focused diversification and high-stringency selection to improve binding behavior while monitoring expression and specificity.
Network & Ecosystem
Proud Member Of
Connected to a Bay Area biotech ecosystem supporting discovery, shared infrastructure, and collaborative R&D.
Supporting Biotech Teams Worldwide from the San Francisco Bay Area
Share your target format, project goal, and desired binder profile. We’ll help map the fastest practical path toward a focused yeast display discovery campaign.
Contact Us